Safety and Efficacy of 177Lutetium-PSMA-617 Radioligand Therapy Shortly after Failing 223Radium-Dichloride. Baumgarten J, Groener D, Nguyen Ngoc C, Mader N, Chaurasia M, Davis K, Wichert J, Chun FKH, Tselis N, Happel C, Grünwald F, Sabet A.Cancers (Basel). 2022 Jan 22;14(3):557

Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis. Roll W, Schindler P, Masthoff M, Seifert R, Schlack K, Bögemann M, Stegger L, Weckesser M, Rahbar K.Cancers (Basel). 2021 Jul 30;13(15):3849.

Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer.Mader N, Groener D, Tselis N, Banek S, Nagarajah J, Grünwald F, Sabet A.Cancers (Basel). 2021 Aug 20;13(16):4193.